diversified chemical portfolio is driving earnings. The company benefits from business restructuring and cost-cutting measures. The Performance Chemicals business continues to outperform with an enhanced product mix achieved from the Genovique Specialty acquisition. Strong Specialty margins look increasingly credible.
We are also getting optimistic about the
Performance Polymer business, where Eastman has reversed
losses. We are positive on the company s plans of divesting its
PET business under the segment. We upgrade Eastman to
Outperform from the previous Neutral recommendation and
raise our target price to $77.00 from the initial $58.00.
EASTMAN CHEM CO (EMN): Free Stock Analysis Report
Zacks Investment Research
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.